Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug delivery development deal for Bespak:

This article was originally published in Clinica

Executive Summary

The developer of drug delivery technologies, Bespak (Milton Keynes), has agreed to collaborate with fellow UK company, Innovata Biomed (IB), the respiratory division of ML Laboratories, on the development of IB's C200 multi-dose dry powder inhaler device, used to deliver combination drug therapies for diseases such as asthma. Bespak will manufacture the devices on a pilot scale as required for the clinical trial of the therapy. According to ML Laboratories, IB has already found a European distributor - whose name was not disclosed - for the C200 inhaler, following "a multi-million pound licensing agreement".

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT059034

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel